SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-19-154033
Filing Date
2019-05-22
Accepted
2019-05-22 16:08:03
Documents
14
Period of Report
2019-06-17
Effectiveness Date
2019-05-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A d744352ddef14a.htm DEF 14A 523928
2 GRAPHIC g744352g01e90.jpg GRAPHIC 27799
3 GRAPHIC g744352snap0017.jpg GRAPHIC 11319
4 GRAPHIC g744352snap0020.jpg GRAPHIC 6728
5 GRAPHIC g744352snap0021.jpg GRAPHIC 18959
6 GRAPHIC g744352sp52a.jpg GRAPHIC 16053
7 GRAPHIC g744352sp52d.jpg GRAPHIC 860
8 GRAPHIC g744352sp52f.jpg GRAPHIC 1137
9 GRAPHIC g744352sp52g.jpg GRAPHIC 1220
10 GRAPHIC g744352sp52h.jpg GRAPHIC 2378
11 GRAPHIC g744352sp52i.jpg GRAPHIC 1128
12 GRAPHIC g744352sp52j.jpg GRAPHIC 1520
13 GRAPHIC g744352sp53d.jpg GRAPHIC 1540
14 GRAPHIC g744352spp52b.jpg GRAPHIC 20424
  Complete submission text file 0001193125-19-154033.txt   679833
Mailing Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38295 | Film No.: 19845823
SIC: 2836 Biological Products, (No Diagnostic Substances)